This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

GXD-Bio defeats Myriad’s preliminary objection in UPC patent infringement case

( February 20, 2025, 16:48 GMT | Official Statement) -- MLex Summary: The Unified Patent Court has rejected the preliminary objection raised by Myriad International, Myriad Genetics and its European subsidiaries in a patent infringement case brought by GXD-Bio Corporation. The defendants argued that the court lacked jurisdiction over certain claims predating GXD-Bio’s registration as the patent proprietor. However, the court ruled that the objection did not fall under the grounds listed in Rule 19.1 regarding preliminary objections of the Rules of Procedure, and that the UPC has jurisdiction under the relevant Article 32(1)(a) of the UPC Agreement. The proceedings will continue and an appeal is permitted, the UPC Local Division Munich ordered.See court document attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections